twenty patients with paralysis agitans took part in a double-blind , cross-over investigation of cb 154 ( 2-bromo-alpha-ergocryptine ) and madopar ( l-dopa + benserazid ( a peripheral decarboxylase inhibitor ) , dose ratio 4:1 ) .
C0030567
paralysis agitans
C0006230
2-bromo-alpha-ergocryptine